1. Borowy-Borowski, H., Lipman, R., Chowdary, D., and Tomasz, M., 1990, Duplex oligodeoxyribonucleotides cross-linked by mitomycin C at a single site: synthesis, properties, and cross-link reversibility, Biochemistry
29: 2992–2999.
2. Bowman, A., Twelves, C., Hoekman, K., Simpson, A., Smyth, J., Vermorken, J., Höppener, F., Beijnen, J., Vega, E., Jimeno, J., and Hanauske, A.-R., 1998, Phase I clinical and pharmacokinetic (PK) study of ecteinascidin-743 (Et-743) given as a one-hour infusion every 21 days, Ann. Oncol. 9 (suppl. 2):119.
3. Corey, E. J., Gin, D. Y., and Kania, R. S., 1996, Enantioselective total synthesis of ecteinascidin 743, J. Am. Chem. Soc. 118: 9202–9203.
4. Cvitkovic, E., Mekranter, B., Taamma, A., Goldwasser, F., Beijnen, J. H., Jimeno, J., Riofrio, M., Vega, E., Misset, J. L., and Hop, P., 1998, Ecteinascidin-743 (Et-743) 24-hour continuous intravenous infusion (CI) phase I study in solid tumors (ST) patients, Ann. Oncol. 9 (suppl. 2):119.
5. D’Incalci, M., 1999, Mode of action of ecteinascidin-743 (Et-743), in AACR-NCI-EORTC International Conference, p. 3872, Washington, D.C.